S. Russ Price
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
S. Russ Price has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Bin Zheng
Renal Division, Department of Medicine, Emory University, Atlanta, Georgia, United States of America
3 shared publicationsJennifer L. Gooch
Renal Division, School of Medicine, Emory University, Atlanta, Georgia
2 shared publicationsRonald Ordas
Renal Division, School of Medicine, Emory University, Atlanta, Georgia 30322
2 shared publications- Tiffany K. Roberts
Jewish Hospital Trager Transplant Center, 200 Abraham Flexner Way, Louisville, KY 40202, United States
2 shared publications Haiyan Li
Renal Division Emory University School of Medicine Emory University Atlanta Georgia USA
1 shared publicationJames L. Bailey
Renal Division, School of Medicine, Emory University, Atlanta, Georgia 30322
1 shared publication
Latest Publications
- Open Access
- 12 July 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (7) , e0159181
Glucocorticoids Alter CRTC-CREB Signaling in Muscle Cells: Impact on PGC-1α Expression and Atrophy Markers
Muscle wasting associated with chronic diseases has been linked to decreased expression of PGC-1α and overexpression of PGC-1α counters muscle loss. CREB, in conjunction with the CREB-regulated transcription coactivator (CRTC2), is a positive modulator of PGC-1α transcription. We previously reported that PGC-1α expression is decreased in skeletal muscle of diabetic rats despite a high level of CREB phosphorylation (i.e., activation), suggesting that CRTC2-CREB signaling may be dysregulated. In this study, the relationship between CREB/CRTC signaling and PGC-1α expression was examined in L6 myotubes treated with dexamethasone (Dex, 48h) to induce atrophy. Dex decreased PGC-1α mRNA and protein as well as the levels of CRTC1 and CRTC2 in the nucleus. Dex also altered the nuclear levels of two known regulators of CRTC2 localization; the amount of calcinuerin catalytic A subunit (CnA) was decreased whereas SIK was increased. To assess PGC-1α transcription, muscle cells were transfected with a PGC-1α luciferase reporter plasmid (PGC-1α-Luc). Dex suppressed PGC-1α luciferase activity while both isobutylmethylxanthine (IBMX) and over-expression of CRTC1 or CRTC2 increased PGC-1α-Luc activity. Mutation of the CRE binding site from PGC-1α-Luc reporter attenuated the responses to both IBMX and the CRTC proteins. Consistent with the reporter gene results, overexpression of CRTC2 produced an increase in CRTC2 in the nucleus and in PGC-1α mRNA and PGC-1α protein. Overexpression of CRTC2 was not sufficient to prevent the decrease in PGC-1α mRNA or protein by Dex. In summary, these data suggest that attenuated CREB/CRTC signaling contributes to the decrease in PGC-1α expression during atrophy.
- 12 July 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (7) , e0159181
Open AccessGlucocorticoids Alter CRTC-CREB Signaling in Muscle Cells: Impact on PGC-1α Expression and Atrophy Markers
Muscle wasting associated with chronic diseases has been linked to decreased expression of PGC-1α and overexpression of PGC-1α counters muscle loss. CREB, in conjunction with the CREB-regulated transcription coactivator (CRTC2), is a positive modulator of PGC-1α transcription. We previously reported that PGC-1α expression is decreased in skeletal muscle of diabetic rats despite a high level of CREB phosphorylation (i.e., activation), suggesting that CRTC2-CREB signaling may be dysregulated. In this study, the relationship between CREB/CRTC signaling and PGC-1α expression was examined in L6 myotubes treated with dexamethasone (Dex, 48h) to induce atrophy. Dex decreased PGC-1α mRNA and protein as well as the levels of CRTC1 and CRTC2 in the nucleus. Dex also altered the nuclear levels of two known regulators of CRTC2 localization; the amount of calcinuerin catalytic A subunit (CnA) was decreased whereas SIK was increased. To assess PGC-1α transcription, muscle cells were transfected with a PGC-1α luciferase reporter plasmid (PGC-1α-Luc). Dex suppressed PGC-1α luciferase activity while both isobutylmethylxanthine (IBMX) and over-expression of CRTC1 or CRTC2 increased PGC-1α-Luc activity. Mutation of the CRE binding site from PGC-1α-Luc reporter attenuated the responses to both IBMX and the CRTC proteins. Consistent with the reporter gene results, overexpression of CRTC2 produced an increase in CRTC2 in the nucleus and in PGC-1α mRNA and PGC-1α protein. Overexpression of CRTC2 was not sufficient to prevent the decrease in PGC-1α mRNA or protein by Dex. In summary, these data suggest that attenuated CREB/CRTC signaling contributes to the decrease in PGC-1α expression during atrophy.
- 30 September 2010
- Published by Elsevier in Journal of Renal Nutrition
- Vol. 20 (5) , S24-S28
Muscle Atrophy in Chronic Kidney Disease Results From Abnormalities in Insulin Signaling
- 30 September 2010
- Published by Elsevier in Journal of Renal Nutrition
- Vol. 20 (5) , S24-S28
Muscle Atrophy in Chronic Kidney Disease Results From Abnormalities in Insulin Signaling
- 1 August 2010
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1803 (8) , 960-967
Calcineurin signaling and PGC-1α expression are suppressed during muscle atrophy due to diabetes
- 1 August 2010
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1803 (8) , 960-967
Calcineurin signaling and PGC-1α expression are suppressed during muscle atrophy due to diabetes
- Open Access
- 6 April 2010
- Published by Wiley in The FASEB Journal
- Vol. 24 (8) , 2660-2669
FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin‐1/MAFbx expression during glucocorticoid‐induced skeletal muscle atrophy
Muscle atrophy is a consequence of chronic diseases ( e.g ., diabetes) and glucocorticoid‐induced insulin resistance that results from enhanced activity of the ubiquitin‐proteasome pathway. The PI3K/Akt pathway inhibits the FOXO‐mediated transcription of the muscle‐specific E3 ligase atrogin‐1/MAFbx (AT‐1), whereas the MEK/ERK pathway increases Sp1 activity and ubiquitin (UbC) expression. The observations raise a question about how the transcription of these atrogenes is synchronized in atrophic muscle. We tested a signaling model in which FOXO3a mediates crosstalk between the PI3K/Akt and MEK/ERK pathways to coordinate AT‐1 and UbC expression. In rat L6 myotubes, dexamethasone (≥24 h) reduced insulin receptor substrate (IRS)‐1 protein and PI3K/Akt signaling and increased AT‐1 mRNA. IRS‐2 protein, MEK/ERK signaling, Sp1 phosphorylation, and UbC transcription were simultaneously increased. Knockdown of IRS‐1 using small interfering RNA or adenovirus‐mediated expression of constitutively activated FOXO3a increased IRS‐2 protein, MEK/ERK signaling, and UbC expression. Changes in PI3K/Akt and MEK/ERK signaling were recapitulated in rat muscles undergoing atrophy due to streptozotocin‐induced insulin deficiency and concurrently elevated glucocorticoid production. IRS‐1 and Akt phosphorylation were decreased, whereas MEK/ERK signaling and expression of IRS‐2, UbC and AT‐1 were increased. We conclude that FOXO3a mediates a reciprocal communication between the IRS‐1/PI3K/Akt and IRS‐2/MEK/ERK pathways that coordinates AT‐1 and ubiquitin expression during muscle atrophy.—Zheng, B., Ohkawa, S., Li, H., Roberts‐Wilson, T.‐K., Price, S. R. FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin‐1/MAFbx expression during glucocorticoid‐induced skeletal muscle atrophy. FASEB J . 24, 2660–2669 (2010). www.fasebj.org
- 6 April 2010
- Published by Wiley in The FASEB Journal
- Vol. 24 (8) , 2660-2669
Open AccessFOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin‐1/MAFbx expression during glucocorticoid‐induced skeletal muscle atrophy
Muscle atrophy is a consequence of chronic diseases ( e.g ., diabetes) and glucocorticoid‐induced insulin resistance that results from enhanced activity of the ubiquitin‐proteasome pathway. The PI3K/Akt pathway inhibits the FOXO‐mediated transcription of the muscle‐specific E3 ligase atrogin‐1/MAFbx (AT‐1), whereas the MEK/ERK pathway increases Sp1 activity and ubiquitin (UbC) expression. The observations raise a question about how the transcription of these atrogenes is synchronized in atrophic muscle. We tested a signaling model in which FOXO3a mediates crosstalk between the PI3K/Akt and MEK/ERK pathways to coordinate AT‐1 and UbC expression. In rat L6 myotubes, dexamethasone (≥24 h) reduced insulin receptor substrate (IRS)‐1 protein and PI3K/Akt signaling and increased AT‐1 mRNA. IRS‐2 protein, MEK/ERK signaling, Sp1 phosphorylation, and UbC transcription were simultaneously increased. Knockdown of IRS‐1 using small interfering RNA or adenovirus‐mediated expression of constitutively activated FOXO3a increased IRS‐2 protein, MEK/ERK signaling, and UbC expression. Changes in PI3K/Akt and MEK/ERK signaling were recapitulated in rat muscles undergoing atrophy due to streptozotocin‐induced insulin deficiency and concurrently elevated glucocorticoid production. IRS‐1 and Akt phosphorylation were decreased, whereas MEK/ERK signaling and expression of IRS‐2, UbC and AT‐1 were increased. We conclude that FOXO3a mediates a reciprocal communication between the IRS‐1/PI3K/Akt and IRS‐2/MEK/ERK pathways that coordinates AT‐1 and ubiquitin expression during muscle atrophy.—Zheng, B., Ohkawa, S., Li, H., Roberts‐Wilson, T.‐K., Price, S. R. FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin‐1/MAFbx expression during glucocorticoid‐induced skeletal muscle atrophy. FASEB J . 24, 2660–2669 (2010). www.fasebj.org
- 1 December 2008
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 105 (6) , 1772-1778
Regulation of caspase-3 activity by insulin in skeletal muscle cells involves both PI3-kinase and MEK-1/2
A hallmark of skeletal muscle atrophy is increased activities of several proteolytic systems, including caspase-3. We have previously shown that conditions involving insulin deficiency or insulin resistance increase both overall protein degradation and caspase-3-mediated actin cleavage. In the present experiments, we examined how insulin regulates caspase-3 activity in L6 myotubes. Reducing the serum concentration in the culture media from 2 to 0.5% overnight increased caspase-3 activity and actin cleavage. Addition of insulin to proteolytically active cells attenuated both responses within 4 h. Individually, inhibitors of either phosphatidylinositide 3-kinase (PI3K) or MEK1/2 partially blocked the insulin-induced reduction in caspase-3 activity; in combination, the inhibitors completely prevented insulin from attenuating caspase-3 activity. Insulin suppressed caspase-3 activity by a complex mechanism that included direct inhibition due to an increased interaction between caspase-3 and cellular inhibitor of apoptosis-1 and indirect inhibition via phosphorylation (i.e., inactivation) of the proapoptotic protein Bad, which participates in the intrinsic (i.e., mitochondrial) apoptosis activation cascade. Unlike other cell types, the phosphorylation of Bad Ser112 was mediated by the PI3K/Akt pathway rather than the MEK/ERK/ribosomal S6 protein kinase pathway. In summary, our findings indicate that insulin regulates caspase-3 activity by a multistep process that is unique to skeletal muscle, thus providing insights about the muscle-specific nature of the atrophy process.
- 1 December 2008
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 105 (6) , 1772-1778
Regulation of caspase-3 activity by insulin in skeletal muscle cells involves both PI3-kinase and MEK-1/2
A hallmark of skeletal muscle atrophy is increased activities of several proteolytic systems, including caspase-3. We have previously shown that conditions involving insulin deficiency or insulin resistance increase both overall protein degradation and caspase-3-mediated actin cleavage. In the present experiments, we examined how insulin regulates caspase-3 activity in L6 myotubes. Reducing the serum concentration in the culture media from 2 to 0.5% overnight increased caspase-3 activity and actin cleavage. Addition of insulin to proteolytically active cells attenuated both responses within 4 h. Individually, inhibitors of either phosphatidylinositide 3-kinase (PI3K) or MEK1/2 partially blocked the insulin-induced reduction in caspase-3 activity; in combination, the inhibitors completely prevented insulin from attenuating caspase-3 activity. Insulin suppressed caspase-3 activity by a complex mechanism that included direct inhibition due to an increased interaction between caspase-3 and cellular inhibitor of apoptosis-1 and indirect inhibition via phosphorylation (i.e., inactivation) of the proapoptotic protein Bad, which participates in the intrinsic (i.e., mitochondrial) apoptosis activation cascade. Unlike other cell types, the phosphorylation of Bad Ser112 was mediated by the PI3K/Akt pathway rather than the MEK/ERK/ribosomal S6 protein kinase pathway. In summary, our findings indicate that insulin regulates caspase-3 activity by a multistep process that is unique to skeletal muscle, thus providing insights about the muscle-specific nature of the atrophy process.